(Albany, US) October 14, 2026 – DelveInsight’s “Melanoma Pipeline Insights 2026” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in the Melanoma Pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Melanoma research @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight
Key Takeaways from the Melanoma Pipeline Report
- On October 07, 2026 – Natera announced the enrollment of the first patients in a new melanoma clinical trial. The study, sponsored by NYU Langone Health, will evaluate Natera’s Signatera molecular residual disease (MRD) testing to guide treatment escalation in patients with advanced or metastatic melanoma. The trial aims to identify patients who may benefit from more intensive treatment before the cancer progresses on imaging.
- On October 07, 2026 – Vaccinex reported new findings on pepinemab in metastatic melanoma. A study published in Nature Communications found that pepinemab, in combination with nivolumab and/or ipilimumab, was associated with changes in the tumor immune environment that may support antitumor immune responses. The study met its primary biomarker endpoint, but it was not designed to establish clinical efficacy
- On October 01, 2026 – Faron Pharmaceuticals dosed the first patient in the BLAZE trial. The Phase 1/2 investigator-initiated trial is evaluating bexmarilimab in combination with nivolumab in patients with melanoma and non-small cell lung cancer whose disease has progressed following previous immunotherapy. The study will assess the safety and antitumor activity of the combination
- DelveInsight’s Melanoma pipeline report depicts a robust space with 150+ active players working to develop 180+ pipeline therapies for Melanoma treatment.
- The leading Melanoma Companies such as Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier, IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, and Immatics US Inc. and others.
- Promising Melanoma Therapies such as Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
Download for updates and be a part of the revolution in cancer care @ Melanoma Clinical Trials Assessment
The Melanoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Melanoma Pipeline Report also highlights the unmet needs with respect to the Melanoma.
Melanoma Overview
Melanoma is a malignant tumour arising from melanocytes. It is among the most common forms of cancer in young adults and typically presents as a new or changing pigmented (brown or black) skin lesion, but there are other presentations (amelanotic or desmoplastic) with a different clinical picture. When melanoma starts in the skin, the disease is called cutaneous melanoma. Melanoma is more aggressive than basal cell skin cancer or squamous cell skin cancer. Melanoma of the skin can occur anywhere on the body. Unusual moles, exposure to natural sunlight or artificial sunlight (such as from tanning beds) over long periods of time, and family history can affect the risk of melanoma. Melanoma may also occur in mucous membranes thin, moist layers of tissue that cover surfaces such as the lips.
Melanoma Emerging Drugs Profile
- ABP-206: Amgen
ABP-206 is an investigational biologic being developed by Amgen for the treatment of melanoma. It is designed as a biosimilar candidate to target immune checkpoint pathways involved in tumor growth. By modulating the immune system, ABP-206 aims to enhance anti-tumor responses in patients with advanced or metastatic melanoma. The drug is currently in clinical development, with ongoing studies evaluating its safety, efficacy, and comparability to the reference therapy. The drug is currently is in Phase III for the treatment of Melanoma.
- IBI363: Innovent Biologics
IBI363 is the world’s first PD-1/IL-2α-bias bispecific fusion protein independently developed by Innovent Biologics. It integrates two key functions: blockade of the PD-1/PD-L1 pathway and activation of the IL-2 signaling pathway. The IL-2 arm of IBI363 has been engineered to retain affinity for IL-2 Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm enables simultaneous PD-1 blockage and selective delivery of IL-2. This differential targeting strategy exploits the fact that newly activated tumor-specific T cells co-express PD-1 and IL-2α, which allows for more precise and efficient targeting and activation of this T cell subset. Currently, the drug is in Phase II stage of its development for the treatment of Melanoma.
- EVX-01: Evaxion Biotech A/S
EVX-01 is an investigational cancer immunotherapy developed by Evaxion Biotech A/S for the treatment of melanoma. It is a personalized peptide-based vaccine designed using AI to identify tumor-specific neoantigens unique to each patient. By stimulating a targeted T-cell immune response, EVX-01 aims to improve tumor recognition and destruction. The therapy is currently in clinical development, with studies assessing its safety, immunogenicity, and efficacy in melanoma patients. Currently, the drug is in Phase III for the treatment of Melanoma.
- PF-08046031: Pfizer
PF-08046031 is an investigational antibody–drug conjugate (ADC) developed by Pfizer for the treatment of advanced melanoma and other solid tumors. It targets the CD228 antigen, enabling selective delivery of a cytotoxic agent to tumor cells. This mechanism is designed to enhance tumor cell killing while minimizing systemic exposure. The drug is currently in early-phase clinical development, with studies evaluating its safety, tolerability, and preliminary efficacy in melanoma patients.
- BT02: Biotroy Therapeutics
BT02 is an investigational oncology therapy being developed by Biotroy Therapeutics for the treatment of melanoma. It is designed to target tumor-specific pathways involved in cancer cell growth and survival, aiming to inhibit disease progression. The therapy is being explored for its potential to enhance anti-tumor immune responses or directly suppress tumor activity. BT02 is currently in early-stage development, with ongoing research focused on evaluating its safety and therapeutic potential in melanoma.
Learn more about Melanoma Drugs opportunities in our groundbreaking Melanoma research and development projects @ Melanoma Unmet Needs
The Melanoma Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Melanoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma Treatment.
- Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Melanoma Drugs under development are based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Melanoma market.
Melanoma Companies
Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier, IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, and Immatics US Inc. and others
The Melanoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical
Melanoma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Stay informed about how we’re transforming the future of oncology @ Melanoma Market Drivers and Barriers, and Future Perspectives
Scope of the Melanoma Pipeline Report
- Coverage- Global
- Melanoma Companies- Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier, IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, and Immatics US Inc. and others.
- Melanoma Therapies– Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
- Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Read the full details of the Melanoma Pipeline on our website, @ Melanoma Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Melanoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Comparative Analysis
- ABP-206: Amgen
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IBI363: Innovent Biologics
- Early Stage Products (Phase I)
- Comparative Analysis
- PF-08046031: Pfizer
- Inactive Products
- Melanoma Key Companies
- Melanoma Key Products
- Melanoma Unmet Needs
- Melanoma Market Drivers and Barriers
- Melanoma Future Perspectives and Conclusion
- Melanoma Analyst Views
- Melanoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/melanoma-pipeline-insight